IMVEXXY

Peak

estradiol

NDAVAGINALINSERT
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Estrogen Receptor Agonists

Pharmacologic Class:

Estrogen

Clinical Trials (5)

NCT07446400Phase 1Not Yet Recruiting

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Started Mar 2026
48 enrolled
Healthy Volunteers
NCT07272889Phase 1Not Yet Recruiting

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

Started Dec 2025
24 enrolled
Healthy Volunteer Study
NCT07013643Phase 1Recruiting

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Started Jun 2025
75 enrolled
Healthy Participants
NCT06942936Phase 1Completed

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

Started May 2025
51 enrolled
Healthy Participants
NCT06657105Phase 1Completed

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

Started Nov 2024
22 enrolled
Healthy Participants

Loss of Exclusivity

LOE Date
Feb 2, 2034
96 months away
Patent Expiry
Feb 2, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
9289382
Nov 21, 2032
Product
10398708
Nov 21, 2032
U-2614
10471072
Nov 21, 2032
U-2316
10537581
Nov 21, 2032
Product
U-2316
10568891
Nov 21, 2032
U-2316